Iodixanol - GE Healthcare

Drug Profile

Iodixanol - GE Healthcare

Alternative Names: 2 5410 3A; DU 6807; Visipaque

Latest Information Update: 08 Apr 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Developer Daiichi Sankyo Company; GE Healthcare
  • Class Contrast media; Triiodobenzoic acids
  • Mechanism of Action Radiography enhancers; Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Mar 2014 Final adverse events data from a head-to-head phase IV trial in Cardiovascular disorders (diagnosis) presented at the 63rd Annual Scientific Session of the American College of Cardiology (ACC-2014) .
  • 05 Mar 2014 Final efficacy data from a head to head study in Cardiovascular disorders (diagnosis) released by GE Healthcare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top